We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA |

Highlights FREE

JAMA. 2015;314(20):2107-2109. doi:10.1001/jama.2014.12103.
Text Size: A A A
Published online


Proliferative diabetic retinopathy is a leading cause of vision loss among patients with diabetes. In a clinical trial conducted at 55 sites by the Diabetic Retinopathy Clinical Research Network, investigators randomly assigned 305 adults (394 study eyes) with proliferative diabetic retinopathy to receive standard treatment with panretinal laser photocoagulation or treatment with intravitreal ranibizumab—an antibody that inhibits vascular endothelial growth factor. The investigators report that treatment with ranibizumab resulted in visual acuity that was noninferior to (not worse than) panretinal photocoagulation treatment at a 2-year assessment. In an Editorial, Olsen discusses treatment of proliferative diabetic retinopathy.

New-onset migraine headache is a complication of transcatheter atrial septal defect (ASD) closure. In a randomized trial involving 171 patients with an indication for transcatheter ASD closure and no history of migraine, Rodés-Cabau and colleagues found that compared with antiplatelet therapy with aspirin alone, patients randomly assigned to receive dual antiplatelet therapy with clopidogrel and aspirin had a lower monthly frequency of migraine attacks in the 3 months following ASD closure.

In a multicenter randomized trial involving 1400 patients with long coronary artery lesions (estimated to require stent length >28 mm), Hong and colleagues assessed long-term clinical outcomes following everolimus-eluting stent implant in the target lesion using either intravascular ultrasound (IVUS) guidance or angiographic guidance. The authors report that compared with angiography-guided stent implantation, use of IVUS-guided stent implantation resulted in a significantly lower rate of the composite of major adverse cardiac events at 1 year—primarily due to a lower risk of target lesion revascularization.

Body mass index (BMI) lower than 16.0—the most severe category of adult malnutrition—is associated with substantial morbidity and mortality. In analyses of 1993-2012 data from nationally representative surveys conducted in 60 low- and middle-income countries—representing nearly one-third of the world’s women—Razak and colleagues found that among women aged 20 to 49 years, the prevalence of BMI lower than 16 was 1.8% and was related to poverty and low education.


Callaghan and colleagues review recent diagnostic and therapeutic advances in distal symmetric polyneuropathy—the most common subtype of peripheral neuropathy. The authors found evidence supporting limited routine laboratory testing. Despite their frequent use in the diagnostic evaluation of patients with polyneuropathy, evidence supporting electrodiagnostic testing and magnetic resonance imaging is lacking. Medications with proven efficacy for neuropathic pain are discussed.

A 55-year-old woman, diagnosed with invasive ductal carcinoma of the left breast in December 2012, was treated with neoadjuvant chemotherapy with docetaxel and trastuzumab, followed by 3 courses of epirubicin and cyclophosphamide before undergoing a radical mastectomy. After undergoing adjuvant radiotherapy in September 2013, she developed a generalized asymptomatic rash with red-brown plaques and papules. Computed tomographic scan of her chest and abdomen did not indicate metastasis. What would you do next?

Vascular endothelial growth factor (VEGF) induces angiogenesis and increases vascular permeability and inflammation. This Medical Letter on Drugs and Therapeutics article summarizes information on 4 VEGF inhibitors—administered as periodic intravitreal injections—that reduce leakage from blood vessels, prevent neovascularization, decrease retinal swelling, and improve visual acuity in patients with neovascular (wet) age-related macular degeneration, diabetic macular edema, or macular edema following retinal vein occlusion.



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.